Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®GlobeNewsWire • 09/25/23
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)GlobeNewsWire • 09/20/23
Alvotech to Participate in the Morgan Stanley 21st Annual Global Healthcare ConferenceGlobeNewsWire • 09/11/23
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business UpdateGlobeNewsWire • 08/30/23
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmAccesswire • 08/25/23
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ETGlobeNewsWire • 08/22/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 08/03/23
INVESTIGATION ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/31/23
INVESTOR ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmAccesswire • 07/25/23
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars PartnershipBusiness Wire • 07/24/23
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Alvotech SA - ALVOPRNewsWire • 07/17/23
INVESTIGATION ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmAccesswire • 07/12/23
INVESTOR ACTION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmAccesswire • 07/08/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses In Excess of $100,000 to Contact the FirmAccesswire • 07/07/23
Alvotech Provides Regulatory Update on Second Biologics License Application for AVT02GlobeNewsWire • 06/28/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against Alvotech and Encourages Investors with Losses to Contact the FirmAccesswire • 06/20/23
ALVO, ALVOW INVESTOR NEWS: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Alvotech Investors to Inquire About Securities Class Action Investigation - ALVO, ALVOWPRNewsWire • 06/14/23
Alvotech and Teva Secure U.S. License Date for AVT04, a Proposed Biosimilar to Stelara®Business Wire • 06/12/23